(lp0
S'Paratek Pharmaceuticals, Inc. to Present at LEERINK Partners 6th Annual Global ... GlobeNewswire  - Feb 8, 2017 BOSTON, Feb. 08, 2017  -- Paratek Pharmaceuticals, Inc.  today announced that its President and Chief Operating Officer, Evan Loh, MD, will participate in the LEERINK Partners 6th Annual Global Healthcare Conference&nbsp;...Paratek: CABP Read-Out Likely Positive - Seeking Alpha'
p1
aS'Dissecting And Analyzing The Special Situation In Paratek Pharmaceuticals, Inc. Seeking Alpha - Jan 17, 2017 We then briefly introduced the Reader to Paratek Pharmaceuticals for consideration of a special situation investment, and we ran some probability-weighted, risk-adjusted calculations to arrive at expected annualized returns on investment in order to&nbsp;...Paratek Announces Completion of Enrollment in Omadacycline Phase 3 Community ... - GlobeNewswire '
p2
aS'Paratek Pharmaceuticals Inc. PRTK  Wall Street Journal - Oct 31, 2014 News Paratek Pharmaceuticals Inc.PRTK. Significant News Only. 03/02/17; Press Release. Paratek Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter 2016 Financial Results and Provides Clinical Update. Press Release. 02/22/17; Press Release.'
p3
aS'Paratek Pharmaceuticals Inc.  Moves Higher on Volume Spike for March 15 Equities.com - Mar 15, 2017 Paratek Pharmaceuticals Inc.  traded on unusually high volume on Mar. 15, as the stock gained 1.5% to close at $16.90.The Paratek Pharmaceuticals Inc  Receives Average Rating of Buy from ... - Petro Global News 24Review of Price Trends: Paratek Pharmaceuticals, Inc.  - Is stories'
p4
aS'Omadacycline is shown to be non-inferior to linezolid. Seeking Alpha - Mar 13, 2017 Paratek Pharmaceuticals  has a lot going for it - it has an NDA upcoming in 2018 based on successful acute bacterial skin and skin structure infections  trial  of its drug candidate omadacycline.'
p5
aS'Paratek Pharmaceuticals, Inc.  Valuation in Focus Business Review - 14 hours ago The ERP5 Rank is an investment tool that analysts use to discover undervalued companies. The ERP5 looks at the Price to Book ratio, Earnings Yield, ROIC and 5 year average ROIC.'
p6
aS'Paratek Pharmaceuticals Inc.  Moves Lower on Volume Spike for March 09 Equities.com - Mar 9, 2017 Paratek Pharmaceuticals Inc.  traded on unusually high volume on Mar. 09, as the stock lost 3.82% to close at $16.35.The Paratek Pharmaceuticals Inc  Upgraded to Hold by Zacks Investment ... - DailyQuint'
p7
aS'Paratek Pharmaceuticals Is A Buy For Its Broad-Spectrum Tetracycline Antibiotic Seeking Alpha - May 27, 2016 Paratek Pharmaceuticals is a Boston, Massachusetts based pharmaceuticals company, whose key product in the development is omadacycline, a broad spectrum aminomethylcycline  class of antibiotic.'
p8
aS'Cempra Longs Can Make Their Money Back With Paratek Seeking Alpha - Nov 3, 2016 The macrolide class of antibiotics provides the best treatment option for CABP, due to their spectrum of activity, safety, tissue and intracellular activity and anti-inammatory properties, which give macrolides an advantage over other classes of ...'
p9
aS'Paratek Pharmaceuticals Inc.  Moves Higher on Volume Spike for March 10 Equities.com - Mar 10, 2017 Paratek Pharmaceuticals Inc.  traded on unusually high volume on Mar. 10, as the stock gained 0.61% to close at $16.45.Paratek Pharmaceuticals Inc to Post FY2017 Earnings of  Per Share ... - Chaffey Breeze'
p10
a.